机构：[a]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[b]Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China[c]Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China[d]Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China[e]Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China[f]Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China[g]Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[h]Department of Oncology, Clinical College of Weifang Medical University, Weifang, China[i]Hepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[j]Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Chang Gung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China[k]Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[l]Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China[m]Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China中国医科大学附属盛京医院中国医科大学盛京医院[n]Department of Hepatobiliary Surgery, Zhujiang Hospital, First Military Medical University, Guangzhou, China南方医科大学珠江医院[o]Department of Radiation Oncology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[p]Department of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China首都医科大学附属安贞医院[q]Department of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China[r]Department of Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[s]Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China[t]Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China[u]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[v]Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China[w]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[x]Department of Hepatobiliary Surgery, First Medical Center of Chinese PLA General Hospital, Beijing, China[y]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[z]Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China[A]Department of Oncology, Shanghai Medical College, Fudan University Shanghai, Shanghai, China[B]Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[C]Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China[D]Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China[E]Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China[F]Department of Integrated Traditional Chinese and Western Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[G]Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[H]Division of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China[I]Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China[J]Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China[K]Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[L]Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China[M]Department of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China[N]Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[O]Department of Hepatobiliary and Pancreas Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Huhehot, China[P]Department of Traditional Chinese Medicine, Beijing Weida Traditional Chinese Medicine Tumor Hospital, Beijing, China[Q]Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China[R]Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China[S]Department of Hepatobiliary Surgery, Jiangxi Provincial Cancer Hospital, Nanchang, China[T]Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China[U]Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials. (C) 2022 The Author(s). Published by S. Karger AG, Basel
第一作者机构：[a]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Juxian Sun,Rongping Guo,Xinyu Bi,et al.Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)[J].LIVER CANCER.2022,11(4):315-328.doi:10.1159/000523997.
APA：
Juxian Sun,Rongping Guo,Xinyu Bi,Mengchao Wu,Zhaoyou Tang...&Chinese Association of Liver Cancer and Chinese Medical Doctor Association.(2022).Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).LIVER CANCER,11,(4)
MLA：
Juxian Sun,et al."Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)".LIVER CANCER 11..4(2022):315-328
医学